Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today announced that it has received notification from The NYSE American LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.
In the notification, the NYSE American informed the Company that as of December 27, 2022, the below compliance (“.BS”) indicator will no longer be disseminated and the Company has been removed from the NYSE American noncompliant issuers on the NYSE American’s website.
Source: Biospace